3 Molecular Testing Company, National Pathology Network and Public Partnership Diagnostics Provider Stocks With a Strong Future Roadmap: Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics

Molecular testing and pathology lab stocks let investors follow companies that serve a growing part of the Indian economy. Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics cover a point of care molecular testing company, a national pathology network and a government partnership diagnostics provider.

This list covers three molecular testing and pathology lab stocks with complete current figures: Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics. Every figure comes from the latest reported financials and the 28 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Molecular Testing and Pathology Lab Stocks?

Molecular testing and pathology lab stocks are listed companies that make portable molecular testing systems, run laboratories and collection centres across the country and provide radiology and pathology services through government hospital partnerships. Their earnings depend on test volumes, network reach and service mix.

Molecular Testing and Pathology Lab Stocks at a Glance

On valuation, Metropolis Healthcare and Krsnaa Diagnostics trade at a P/E below the industry P/E, while Molbio Diagnostics trades above it, which reflects the growth the market already expects. Readers comparing molecular testing and pathology lab stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Molecular Testing and Pathology Lab Stocks Have a Strong Roadmap in India?

Molecular testing and pathology lab stocks have a strong roadmap in India because rising health awareness, a shift toward preventive testing and wider access to organised diagnostics keep widening the market for these testing companies.

• Preventive care. More people take regular health tests.
• Wide networks. Collection points bring labs closer to patients.
• Public partnerships. Government hospital tie ups add steady volumes.

Why Molbio Diagnostics Features Among These Molecular Testing and Pathology Lab Stocks

Among the molecular testing and pathology lab stocks on this list, Molbio Diagnostics, based in Goa, develops the Truenat platform, a portable molecular diagnostics system that delivers lab-grade PCR results at the point of care, with strong use in tuberculosis testing.

Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%.

The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6.

Roadmap: Its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.

What to watch: Order timing from public health programmes can be lumpy, so look at annual rather than single-quarter trends.

Why Metropolis Healthcare Features Among These Molecular Testing and Pathology Lab Stocks

Among the testing and pathology shares on this list, Metropolis Healthcare, headquartered in Mumbai, is a pathology and diagnostics company that runs a national network of laboratories, patient service centres and collection points, and also serves hospitals and corporate clients.

In the June 2026 quarter, revenue grew 15.7% year on year to Rs 455 crore, while net profit rose 25.7% to Rs 56.9 crore. Revenue rose from Rs 1,246 crore in FY22 to Rs 1,671 crore in FY26, a compound annual growth rate of 7.6%.

Net profit grew from Rs 143 crore in FY23 to Rs 191 crore in FY26, which works out to a compound annual growth rate of 10.1%. The company has a return on equity of 12.6%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 10,780 crore. The stock trades at a P/E of 53.1, below the industry P/E of 59.6.

Roadmap: The company is deepening its presence in existing regions while extending into new cities through collection points and partner labs. A larger share of specialised tests in oncology, genetics and wellness lifts revenue per patient and helps its mix.

What to watch: Follow test volumes per patient and the pace at which newer regions turn profitable.

Why Krsnaa Diagnostics Features Among These Molecular Testing and Pathology Lab Stocks

Among the three companies on this list, Krsnaa Diagnostics provides radiology and pathology services through partnerships with government hospitals and through its own diagnostic centres across many states.

The company has a return on equity of 10.3%, a debt to equity ratio of 0.55 and a market capitalisation of Rs 1,615 crore. The stock trades at a P/E of 16.6, below the industry P/E of 58.4.

Revenue rose from Rs 470 crore in FY22 to Rs 816 crore in FY26, a compound annual growth rate of 14.8%. Net profit grew from Rs 68.4 crore in FY22 to Rs 101 crore in FY26, which works out to a compound annual growth rate of 10.4%. In the June 2026 quarter, revenue grew 23.3% year on year to Rs 243 crore.

Roadmap: The company is winning new public sector contracts and adding advanced imaging services, which widens its patient reach. Growing demand for affordable diagnostics supports volumes.

What to watch: Track new contract wins, test volumes and the rollout of advanced imaging.

Molbio Diagnostics vs Metropolis Healthcare vs Krsnaa Diagnostics on Key Financials

The table below sets the three molecular testing and pathology lab stocks side by side on revenue, profit and margin, using reported figures.

Molbio Diagnostics posts the highest return on equity in this group at 14.2%. Metropolis Healthcare has the largest FY26 revenue at Rs 1,671 crore, and Molbio Diagnostics shows the fastest revenue growth with a 16.8% compound annual rate. A useful habit with molecular testing and pathology lab stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Molecular Testing and Pathology Lab Stocks

Every theme carries risks that deserve a check before any decision. For these molecular testing and pathology lab stocks, the main points are: Long-term testing and pathology shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Test volumes. Footfall and test mix can vary with seasons.
• Competition. Rivals can influence pricing and market share.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter molecular testing and pathology lab stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Molecular Testing and Pathology Lab Stocks

Molecular testing and pathology lab stocks reward investors who follow demand trends, order books and margins together. Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics each have a clear plan to grow. Based on the 28 October 2026 close, Molbio Diagnostics trades at Rs 1,312.7, Metropolis Healthcare at Rs 551.2 and Krsnaa Diagnostics at Rs 496.45.

Download the Univest iOS App or Univest Android App to track molecular testing and pathology lab stocks, set price alerts and get research-backed stock ideas.

What are molecular testing and pathology lab stocks?

Ans. Molecular testing and pathology lab stocks are listed companies that make portable molecular testing systems, run laboratories and collection centres across the country and provide radiology and pathology services through government hospital partnerships. Their earnings depend on test volumes, network reach and service mix. This list looks at three of them, Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics, using reported FY22 to FY26 financials and the 28 October 2026 closing prices.

Which molecular testing and pathology lab stocks are covered in this list?

Ans. This list covers Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics. Based on the 28 October 2026 close, Molbio Diagnostics traded at Rs 1,312.7, Metropolis Healthcare at Rs 551.2 and Krsnaa Diagnostics at Rs 496.45. Their return on equity ranges from 10.3% to 14.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 16.8%.

Why do molecular testing and pathology lab stocks have a strong future roadmap in India?

Ans. Molecular testing and pathology lab stocks have a strong roadmap in India because rising health awareness, a shift toward preventive testing and wider access to organised diagnostics keep widening the market for these testing companies. The main drivers are as follows. Preventive care. More people take regular health tests. Wide networks. Collection points bring labs closer to patients. Public partnerships. Government hospital tie ups add steady volumes. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Molbio Diagnostics performed financially?

Ans. Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.

How has Metropolis Healthcare performed financially?

Ans. Revenue rose from Rs 1,246 crore in FY22 to Rs 1,671 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 143 crore in FY23 to Rs 191 crore in FY26, which works out to a compound annual growth rate of 10.1%. In the June 2026 quarter, revenue grew 15.7% year on year to Rs 455 crore, while net profit rose 25.7% to Rs 56.9 crore. The company has a return on equity of 12.6%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 10,780 crore. The stock trades at a P/E of 53.1, below the industry P/E of 59.6. Looking ahead, the company is deepening its presence in existing regions while extending into new cities through collection points and partner labs. A larger share of specialised tests in oncology, genetics and wellness lifts revenue per patient and helps its mix.

How has Krsnaa Diagnostics performed financially?

Ans. Revenue rose from Rs 470 crore in FY22 to Rs 816 crore in FY26, a compound annual growth rate of 14.8%. Net profit grew from Rs 68.4 crore in FY22 to Rs 101 crore in FY26, which works out to a compound annual growth rate of 10.4%. In the June 2026 quarter, revenue grew 23.3% year on year to Rs 243 crore. The company has a return on equity of 10.3%, a debt to equity ratio of 0.55 and a market capitalisation of Rs 1,615 crore. The stock trades at a P/E of 16.6, below the industry P/E of 58.4. Looking ahead, the company is winning new public sector contracts and adding advanced imaging services, which widens its patient reach. Growing demand for affordable diagnostics supports volumes.

What risks should investors check before buying molecular testing and pathology lab stocks?

Ans. Investors should check a few risks before buying molecular testing and pathology lab stocks. Test volumes. Footfall and test mix can vary with seasons. Competition. Rivals can influence pricing and market share. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of molecular testing and pathology lab stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 28 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.